USPTO serial 79365471
S-DUAL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 5, 2025
- Examiner
- BLAZICH, JOAN MICHELE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with S-DUAL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brian P. Gregg
Brian P. Gregg McNees Wallace & Nurick100 Pine StreetHarrisburg, PA 17108UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Multiple fusion proteins in raw material form for scientific or medical research use; diagnostic reagents for scientific or research use; enzymes for scientific or research purposes; bispecific antibody being monoclonal antibodies for in vitro scientific or medical research use; cell culture reagents for scientific and research use; monoclonal antibodies for in vitro scientific purposes; microorganisms for scientific or laboratory purposes, other than for medical and veterinary use; biological preparations for scientific or industrial laboratory purposes; fusion proteins in raw material form for scientific or medical research laboratory purposes; polymerase for nucleic acid for scientific or laboratory purposes; biochemical preparations for scientific purposes; double antibody reagents for scientific purposes; double antibody reagents for scientific purposes in biotechnological product development; biological preparations for use in biotechnology, other than for medical and veterinary use; biochemical catalysts; chemical reagents for use in genetic research for non-medical purposes | ACTIVE | — |
| 005 | Reagents for measurement of HBs antibody for medical purposes; crude medicines for the treatment of cardiovascular diseases; pharmaceutical preparations for activating cellular function; colostral antibodies for veterinary purposes; chemico-pharmaceutical preparations for treating ocular diseases; chemical preparations for use in DNA analysis for medical purposes; bacterial preparations for medical and veterinary use; chemical preparations for medical or veterinary purposes, namely, for bispecific or multispecific antibodies and derivatives thereof, to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, neurological disorder and for related diagnostic or therapeutic use, and for use in related assays; biotechnological preparations being reagents for medical purposes; biological reagents for medical purposes; biochemical preparations for medical use, namely, for bispecific or multispecific antibodies and derivatives thereof, to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, neurological disorder and for related diagnostic or therapeutic use, and for use in related assays; reagents for medical use; reagent paper for medical purposes; bispecific colostral antibody for medical purposes; medical diagnostic test strips for use in the field of blood analysis; trace element preparations for human use, namely, dietary and nutritional supplements; clinical medical reagents; therapeutic drugs for treating cancer and drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; antigens being pharmaceutical preparations for stimulating immune responses; colostral antibodies for medical purposes | ACTIVE | — |
| 042 | Research relating to science, namely, scientific research; multiple nucleic acid scientific analysis; molecular scientific analysis; development of biotechnology; biochemical analysis; drug discovery services; new product design services; pharmaceutical research and development; clinical research in the field of medicine; services for assessing the efficiency of pharmaceuticals, namely, product quality testing; fusion protein scientific analysis; computer programming services in the medical field; medical laboratories; computer project management services relating to imaging medical data; medicine research being medical research; analysis and evaluation of medical product development, namely, product quality testing; providing scientific information on the testing, inspection and research of medical products; scientific laboratory services relating to the production of bispecific antibody; drug development of bispecific antibody; scientific research and development for double antibody reagent; evaluating of clinical trial progress, namely, conducting clinical trials for others; conducting clinical trials for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Samsung Biologics Co., Ltd.
- Other trademarks owned by Samsung Biologics Co., Ltd.
- Other trademarks owned by Samsung Biologics Co., Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named S-DUAL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 5, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 12, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 12, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 5, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 5, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 5, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 17, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 17, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 16, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 15, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 15, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 15, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 15, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 6, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 6, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 31, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 14, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 14, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 20, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 20, 2024 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| May 20, 2024 | PETG | PETITION TO REVIVE-GRANTED | — |
| May 20, 2024 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| May 16, 2024 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 16, 2024 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 16, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 22, 2023 | RFNP | REFUSAL PROCESSED BY IB | — |
| Nov 2, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 2, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 2, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 1, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 24, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 20, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 16, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |